Mydecine Innovations Group has been building momentum with a string of recent announcements.
Mydecine Innovations Group has been building momentum with a string of recent announcements.
Intelligent diversification is the key to investing in this emerging industry.
Globally, over 1 billion people are substance abusers. The U.S. addiction treatment market is already a $35 billion per year industry. Psychedelic drugs may be the (better) answer.
Seniors are now the fastest-growing demographic of cannabis consumers. This same pattern may play out as psychedelic drugs are legalized and commercialized.
The time is ripe for entry into psychedelics stocks.
Microdose-based psychedelic drug therapies have several advantages , ranging from R&D and drug licensing all the way through to drug commercialization and market penetration. It all adds up to greater profit potential.
A 2018 report estimates that mental health issues could cost the global economy $16 trillion between now and 2030. Psychedelic drugs are needed to mitigate those costs.
Oregon could become the first U.S. state to LEGALIZE the (medicinal) use of a psychedelic drug.
Psychedelic drug R&D is ramping up rapidly. The number of past and current clinical studies on these substances will surprise you.
Understanding the drug approval process that leads to drug patents and drug licensing is of critical importance for successful investing in psychedelics.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now